Ikaria, Inc. is a fully-integrated biotherapeutics company focused on developing and commercializing innovative therapeutics designed to meet the significant unmet medical needs of critically ill patients. Its singular focus on critical care, combined with strengths in research and development, manufacturing, and sales and marketing, position Ikaria to be a leader in the critical care market. The company’s lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies. INOMAX® (nitric oxide) for inhalation, the drug included in the INOtherapy offering, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term infants. INOtherapy also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. The company is conducting and planning clinical trials of INOMAX for additional indications and is developing advanced INOMAX drug-delivery systems. Ikaria acquired the North American and Australian rights to LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as the exclusive worldwide license to IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The company also has a number of investigational compounds in development.
Today’s Ikaria was formed in 2007 from the merger between Ikaria, Inc. and INO Therapeutics LLC. New Mountain acquired Ikaria and INO Therapeutics proactively and on an exclusively negotiated basis, based on work in the medical industry which began almost three years before the initial investment was made. New Mountain formed a strategic alliance with the legacy Ikaria company to pursue INO Therapeutics in February 2006 and conducted over 11 months of due diligence work on both companies.